



L Number	Hits	Search Text	DB	Time stamp
1	3258	((546/211) or (546/194) or (514/318) or (514/326)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/28 18:34



chain nodes :

28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 16 17 18 19 20 21

ring/chain nodes :

29

chain bonds :

2-18 21-28 28-29

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 16-17 16-21 17-18 18-19

19-20 20-21

exact/norm bonds :

1-2 1-5 2-3 2-18 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 16-17 16-21 17-18 18-19

19-20 20-21 21-28 28-29

isolated ring systems :

containing 1 : 6 : 16 :

G1:C,O,S,N

G2:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 28:CLASS 29:CLASS

=>


Uploading 10024665.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:49:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15545 TO ITERATE

6.4% PROCESSED 1000 ITERATIONS

3 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 303443 TO 318357

PROJECTED ANSWERS: 523 TO 1341

L2 3 SEA SSS SAM L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L3 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L4 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10024665.str

L5 STRUCTURE UPLOADED

=> que L5 AND L3 NOT L4

L6 QUE L5 AND L3 NOT L4


=> d 16

L6 HAS NO ANSWERS

L3 SCR 1840

L4 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L5 STR



G1 C,O,S,N

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

L6 QUE L5 AND L3 NOT L4

=> s 16 sss sam

SAMPLE SEARCH INITIATED 15:55:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 12850 TO ITERATE

7.8% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

10/024,665

PROJECTED ITERATIONS: 250217 TO 263783
PROJECTED ANSWERS: 42 TO 472

L7 1 SEA SSS SAM L5 AND L3 NOT L4

=> s 16 sss ful
FULL SEARCH INITIATED 15:56:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 255186 TO ITERATE

100.0% PROCESSED 255186 ITERATIONS 406 ANSWERS
SEARCH TIME: 00.00.07

L8 406 SEA SSS FUL L5 AND L3 NOT L4

=> s 18

L9 25 L8

=> d 19 1-25 bib,ab,hitstr

L9 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2003:261680 CAPLUS

DN 138:273308

TI Process for making substituted pyrazoles and pharmaceutical compositions thereof

IN Allen, Kimberly K.; Anderson, Dennis K.; Baldus, John E.; Clark, Jerry D.; Edeny, Albert D.; Lau, Patrick H.; McDermott, Lisa L.; Moe, Jodi L.; Mudipalli, Partha S.; Naing, Win; Selness, Shaun R.; Seymour, Christine B.; Viswanath, Shekhar; Walker, John K.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

not prior

Article 3 sub. on the pyrazole

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026663	A1	20030403	WO 2002-US30409	20020925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-324987P P 20010925

US 2002-381261P P 20020517

US 2002-383691P P 20020528

OS MARPAT 138:273308

AB This invention is directed to a process for making substituted pyrazoles, (I) tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers, wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification. The process comprises: forming a mixt. by a process comprising introducing a hydrazone (II) and an optionally-substituted benzoyl halide (III) into a reactor, and heating the mixt. to a temp. of greater than 50 .degree.C (II); and (III). Thus, N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole was synthesized and used in a pharmaceutical compn. The substituted pyrazoles inhibits p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

IT **271576-80-8P**, N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole **503443-67-2P**, tert-Butyl-4-[5-(4-chlorophenyl)-1-[94-methylphenyl)sulfonyl]-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidine-1-carboxylate



RL: BUU (Biological use, unclassified); IMF (Industrial manufacture); PRP (Properties); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; synthesis of substituted pyrazoles for pharmaceutical uses)


RN 271576-80-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 503443-67-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-(4-chlorophenyl)-1-[(4-methylphenyl)sulfonyl]-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





IT **271576-81-9P**, N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole monohydrochloride
 RL: BUU (Biological use, unclassified); IMF (Industrial manufacture); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of substituted pyrazoles for pharmaceutical uses)


RN 271576-81-9 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2003:261679 CAPLUS

DN 138:292742

TI Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole

IN Allen, Kimberley C.; Clark, Jerry D.; Fraher, Thomas P.; Hanko, Jason A.; Kolbert, Kimberly L.; Little, Clay R.; Mao, Michael K.; Miyake, Patricia J.; Schilke, Tobin C.; Sheikh, Ahmad Y.; Yalamanchili, Gopichand; Mudipalli, Partha S.; Moe, Jodi L.; Seymour, Christine B.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026662	A1	20030403	WO 2002-US30538	20020925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-324987P P 20010925

AB Cryst. forms of the p38 kinase inhibitor N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole (I) are provided. These cryst. forms include (a) a first anhyd. cryst. form possessing improved phys. stability relative to other solid-state forms of the compd.; (b) a second anhyd. cryst. form possessing unique properties relative to other solid-state forms of the compd.; (c) a third anhyd. cryst. form possessing unique properties relative to other solid-state forms of the compd.; and (d) solvated cryst. forms, hydrated cryst. forms, and cryst. salt forms of the compd. that are useful, for example, as intermediate solid-state forms in the prepn. of other cryst. forms of the compd. Also provided are combinations and pharmaceutical compns. comprising at least one of these cryst. forms, processes for prepg. these cryst. forms and for prepg. compns. comprising these cryst. forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amt. of at least one of these cryst. forms. For example, prepn. of acetic acid solvate and N-methylpyrrolidone solvate of I was presented.

IT 271576-80-8P 503834-88-6P 503834-90-0P

503834-94-4P



RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of cryst. forms of heteroaryl pyrazole compd. as p38 kinase inhibitor)


RN 271576-80-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





RN 503834-88-6 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, acetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 271576-80-8
 CMF C20 H20 Cl N5 O2

PAGE 1-A




PAGE 2-A





CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 503834-90-0 CAPLUS
CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, dihydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 2 H₂O

RN 503834-94-4 CAPLUS
 CN 2-Pyrrolidinone, 1-methyl-, compd. with 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)piperidine (9CI) (CA INDEX NAME)


CM 1

CRN 271576-80-8
 CMF C20 H20 Cl N5 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 872-50-4
CMF C5 H9 N O



IT 503834-89-7P 503834-91-1P 503834-92-2P
503834-93-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cryst. forms of heteroaryl pyrazole compd. as p38 kinase
inhibitor)



RN 503834-89-7 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-


10/024,665

(hydroxyacetyl)-, monohydrate (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




● H₂O

RN 503834-91-1 CAPLUS
CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





● Na

RN 503834-92-2 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, methanesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 271576-80-8
 CMF C20 H20 Cl N5 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S





RN 503834-93-3 CAPLUS
CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, 4-methylbenzenesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 271576-80-8
CMF C20 H20 Cl N5 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



IT 503443-67-2P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of cryst. forms of heteroaryl pyrazole compd. as p38 kinase inhibitor)

RN 503443-67-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[5-(4-chlorophenyl)-1-[(4-

methylphenyl)sulfonyl]-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-,
1,1-dimethylethyl ester (9Cl) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:178482 CAPLUS
 DN 138:331397
 TI Discovery of a Potent Small Molecule IL-2 Inhibitor through Fragment Assembly
 AU Braisted, Andrew C.; Oslob, Johan D.; Delano, Warren L.; Hyde, Jennifer; McDowell, Robert S.; Waal, Nathan; Yu, Chul; Arkin, Michelle R.; Raimundo, Brian C.
 CS Sunesis Pharmaceuticals, South San Francisco, CA, 94080, USA
 SO Journal of the American Chemical Society (2003), 125(13), 3714-3715
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 AB Using a site-directed fragment discovery method called tethering, we have identified a 60 nM small mol. antagonist of a cytokine/receptor interaction (IL-2/IL2R.alpha.) with cell-based activity. Starting with a low micromolar hit, we employed a combination of tethering, structural biol., and computational anal. to design a focused set of 20 compds. Eight of these compds. were at least 5-fold more active than the original hit. One of these compds. showed a 50-fold enhancement and represents the highest affinity inhibitor reported against this protein-protein target class. This method of coupling selected fragments with a low micromolar hit shows great potential for generating high-affinity lead compds.
 IT 515845-98-4P 515846-00-1P 515846-04-5P
 515846-08-9P 515846-19-2P 515846-21-6P
 515846-64-7P 515846-67-0P 515846-70-5P
 515846-72-7P 515846-75-0P 515846-79-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (discovery of IL-2 inhibitor through fragment assembly)
 RN 515845-98-4 CAPLUS
 CN Pentanamide, 2-[(aminoiminomethyl)amino]-N-[2-[4-[3-(2,3-dichloro-4-methoxyphenyl)-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 515846-00-1 CAPLUS
 CN Pentanamide, 2-[(aminoiminomethyl)amino]-N-[2-[4-[3-[2,3-dichloro-4-(phenylmethoxy)phenyl]-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 515846-04-5 CAPLUS
 CN Benzoic acid, 4-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 1-A

—CO₂H

RN 515846-08-9 CAPLUS

CN Benzoic acid, 4-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 515846-19-2 CAPLUS

CN Benzoic acid, 3-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—CO₂H

RN 515846-21-6 CAPLUS


CN 2-Furancarboxylic acid, 5-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Bu-i

RN 515846-64-7 CAPLUS
 CN Pentanamide, 2-[(aminoiminomethyl)amino]-N-[2-[4-[3-(2,3-dichloro-4-methoxyphenyl)-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]-4-methyl-, (2R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 515845-98-4
 CMF C25 H35 Cl2 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 515846-67-0 CAPLUS


CN Pentanamide, 2-[(aminoiminomethyl)amino]-N-[2-[4-[3-[2,3-dichloro-4-(phenylmethoxy)phenyl]-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]-4-methyl-, (2R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 515846-00-1

CMF C31 H39 Cl2 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 515846-70-5 CAPLUS

CN Benzoic acid, 4-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 515846-04-5

CMF C32 H39 Cl2 N7 O5

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO₂H

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 515846-72-7 CAPLUS



CN Benzoic acid, 4-[[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 515846-08-9

CMF C33 H41 Cl2 N7 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 515846-75-0 CAPLUS

CN Benzoic acid, 3-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 515846-19-2

CMF C32 H39 Cl2 N7 O5

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO₂H

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 515846-79-4 CAPLUS

CN 2-Furancarboxylic acid, 5-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 515846-21-6


CMF C30 H37 Cl2 N7 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Bu-i

CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 515846-12-5 515846-15-8 515846-18-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(discovery of IL-2 inhibitor through fragment assembly)


RN 515846-12-5 CAPLUS

CN Benzoic acid, 4-[2-[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-


dichlorophenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 515846-15-8 CAPLUS


CN Benzeneacetic acid, 4-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 515846-18-1 CAPLUS

CN Benzoic acid, 4-[[4-[5-[1-[[[(2R)-2-[(aminoiminomethyl)amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CO₂H

IT 515846-36-3P 515846-39-6P 515846-42-1P

515846-46-5P 515846-48-7P 515846-52-3P

515846-55-6P 515846-59-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(discovery of IL-2 inhibitor through fragment assembly)

RN 515846-36-3 CAPLUS

CN Carbamic acid, [(1R)-1-[[[2-[4-[3-(2,3-dichloro-4-hydroxyphenyl)-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 515846-39-6 CAPLUS


CN 2-Furancarboxylic acid, 5-[[2,3-dichloro-4-[5-[1-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]phenoxy]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Bu-i

RN 515846-42-1 CAPLUS


CN 2-Furancarboxylic acid, 5-[[[2,3-dichloro-4-[5-[1-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Bu-i

RN 515846-46-5 CAPLUS


CN Benzoic acid, 3-[[[2,3-dichloro-4-[5-[1-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]phenoxy]methyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 515846-48-7 CAPLUS


CN Benzoic acid, 3-[[[2,3-dichloro-4-[5-[1-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 515846-52-3 CAPLUS

CN Carbamic acid, [(1R)-1-[[[2-[4-[3-(2,3-dichloro-4-methoxyphenyl)-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME).

Absolute stereochemistry.




RN 515846-55-6 CAPLUS


CN Benzoic acid, 4-[[[2,3-dichloro-4-[5-[1-[[[(2R)-2-[[[1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]phenoxy]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 515846-59-0 CAPLUS


CN Benzoic acid, 4-[[[2,3-dichloro-4-[5-[1-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]phenoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 25 CAPLUS CC-RIGHT 2003 ACS
 AN 2003:150531 CAPLUS
 DN 138:187765

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
 IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew
 J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi

PA G. D. Searle & Company, USA
 SO U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6525059	B1	20030225	US 2000-513351	20000224
	US 6514977	B1	20030204	US 1998-196623	19981120
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-196623	A2	19981120		
	WO 1999-US26007	A1	19991117		
	US 1997-47570P	F	19970522		
	US 1998-82670	A2	19980522		

3 cyclic
 Subst.

on
 pyrazole

OS MARPAT 138:187765


AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prep'd. by soln. phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compd. II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 .mu.M and inhibited tumor necrosis factor .alpha. (TNF.alpha.) and interleukin 1.beta. (IL-1.beta.) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 .mu.M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF.alpha..

IT 271574-55-1P 271574-58-4P

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 271574-55-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-1-(2-propynyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 271574-58-4 CAPLUS


CN 1-Piperazinebutanoic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-.gamma.-oxo- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A



IT 216505-87-2P 216505-90-7P 216505-93-0P
216505-98-5P 216506-00-2P 216523-64-7P
216523-65-8P 216523-66-9P 216523-67-0P
216523-68-1P 216523-69-2P 216523-70-5P
216523-71-6P 216523-72-7P 216523-73-8P
216523-74-9P 216523-75-0P 216523-76-1P
216523-77-2P 216523-78-3P 216523-79-4P
216523-80-7P 216523-81-8P 216523-82-9P
216523-83-0P 216523-84-1P 216523-85-2P
216523-86-3P 216523-87-4P 216523-88-5P
216523-89-6P 216523-90-9P 216523-91-0P
216523-92-1P 216523-93-2P 216523-94-3P
216523-95-4P 216523-96-5P 216523-97-6P
216523-98-7P 216523-99-8P 216524-00-4P
216524-01-5P 216524-02-6P 216524-03-7P
216524-04-8P 216524-05-9P 216524-06-0P
216524-07-1P 216524-08-2P 216524-09-3P
216524-10-6P 216524-11-7P 216524-12-8P
216524-13-9P 216524-14-0P 216524-15-1P
216524-16-2P 216524-17-3P 216524-18-4P
216524-19-5P 216524-20-8P 216524-21-9P
216524-22-0P 216524-23-1P 216524-24-2P
216524-25-3P 216524-26-4P 216524-27-5P
216524-28-6P 216524-29-7P 216524-30-0P
216524-31-1P 216524-32-2P 216524-33-3P
216524-34-4P 216524-35-5P 216524-36-6P
216524-37-7P 216524-38-8P 216524-39-9P
216524-40-2P 216524-41-3P 216524-42-4P
216524-43-5P 216524-44-6P 216524-45-7P
216524-46-8P 216524-47-9P 216524-48-0P
216524-49-1P 216524-50-4P 216524-51-5P
216524-52-6P 216524-53-7P 216524-54-8P
216524-55-9P 216524-56-0P 216524-57-1P
216524-58-2P 216524-59-3P 216524-60-6P
216524-61-7P 216524-62-8P 216524-63-9P
216524-64-0P 216524-65-1P 216524-66-2P
216524-67-3P 216524-68-4P 216524-69-5P
216524-70-8P 216524-71-9P 216524-72-0P
216524-73-1P 216524-74-2P 216524-75-3P
216524-76-4P 216524-77-5P 216524-78-6P
216524-79-7P 216524-80-0P 216524-81-1P
216524-93-5P 216524-94-6P 216524-96-8P
216524-98-0P 216525-00-7P 216525-02-9P
216525-03-0P 216525-04-1P 216525-05-2P
216525-06-3P 216525-07-4P 216525-08-5P
216525-09-6P 216525-10-9P 216525-11-0P
216525-12-1P 216525-13-2P 216525-14-3P
216525-15-4P 216525-16-5P 216525-17-6P
216525-18-7P 216525-19-8P 216525-20-1P
216525-21-2P 216525-23-4P 216525-25-6P
216525-27-8P 216525-29-0P 216525-31-4P
216525-33-6P 216525-34-7P 216525-36-9P
216525-39-2P 216525-41-6P 216525-43-8P
216525-46-1P 216525-48-3P 216525-51-8P
216525-53-0P 216525-55-2P 216525-57-4P
216525-59-6P 216525-61-0P 216525-63-2P
216525-64-3P 216525-65-4P 216525-66-5P
216525-67-6P 216525-68-7P 216525-69-8P

216525-70-1P 216525-71-2P 216525-72-3P
 216525-73-4P 216577-31-0P 271574-56-2P
 271574-57-3P 271574-59-5P 271574-68-6P
 271575-06-5P 271575-63-4P 271576-20-6P
 271576-21-7P 271576-22-8P 271576-23-9P
 271576-24-0P 271576-25-1P 271576-28-4P
 271576-48-8P 271576-49-9P 271576-50-2P
 271576-51-3P 271576-62-6P 271576-78-4P
 271576-79-5P



RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 216505-87-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-90-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-93-0 CAPLUS
CN Piperazine, 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 216505-98-5 CAPLUS



CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 216506-00-2 CAPLUS

CN Piperazine, 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-64-7 CAPLUS

CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-iodobenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-65-8 CAPLUS
 CN Piperidine, 1-(4-fluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-66-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-67-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-68-1 CAPLUS
CN Piperidine, 1-acetyl-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-69-2 CAPLUS
 CN Piperidine, 1-(cyclopropylcarbonyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-70-5 CAPLUS
 CN Piperidine, 1-(3-bromobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-71-6 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-iodobenzoyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 216523-72-7 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(5-isoxazolylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216523-73-8 CAPLUS

CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-74-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-methoxybenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-75-0 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(3-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-76-1 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-77-2 CAPLUS
 CN Piperidine, 1-(2-fluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-78-3 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-79-4 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-
[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-80-7, CAPLUS
 CN Piperidine, 1-(ethylsulfonyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-81-8 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methanesulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-82-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(2-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-83-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-84-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(2-fluorophenyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-85-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-86-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-ethyl-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-87-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(2,4-dimethoxyphenyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-88-5 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-89-6 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-90-9 CAPLUS
CN Piperidine, 1-benzoyl-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-91-0 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-92-1 CAPJUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-93-2 CAPLUS
CN Piperidine, 1-(4-bromobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-94-3 CAPLUS

CN Piperidine, 1-(4-chlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridiny)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-95-4 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-96-5 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




FN 216523-97-6 CAPLUS
 CN Piperidine, 1-(4-cyanobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-98-7 CAPLUS
CN Piperidine, 1-(3-fluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216523-29-8 CAPLUS
 CN Piperidine, 1-(3-chlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-00-4 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(3-methylbenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-01-5 CAPLUS
 CN Piperidine, 1-(3-cyanobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-Q2-6 CAPLUS
 CN Piperidine, 1-(2-chlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-03-7 CAPLUS
 CN Piperidine, 1-(2-bromobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-04-8 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-05-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-methylbenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-06-0 CAPLUS
CN Piperidine, 1-(2,6-difluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




FN 216524-07-1 CAPLUS
 CN Piperidine, 1-(2,5-difluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-
 1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 216524-08-2 CAPLUS
 CN Piperidine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216524-09-3 CAPLUS

CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[2-fluoro-6-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-10-6 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[2-fluoro-5-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-11-7 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[2-fluoro-4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-12-8 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[2-fluoro-3-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-13-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[4-fluoro-3-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-14-0 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[3-

fluoro-5-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-15-1 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[4-fluoro-2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-16-2 CAPTUS
 CN Piperidine, 1-(2,3-difluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-
 1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-17-3 CAPLUS
CN Piperidine, 1-(2,4-difluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-18-4 CAPLUS
 CN Piperidine, 1-(2,6-dichlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-19-5 CAPLUS
CN Piperidine, 1-(3,4-difluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-20-8 CAPLUS
 CN Piperidine, 1-(3,5-difluorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-21-9 CAPLUS
 CN Piperidine, 1-(2,3-dichlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-
 1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216534-22-0 CAPLUS
 CN Piperidine, 1-(2,4-dichlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-23-1 CAPTUS
CN Piperidine, 1-(3,4-dichlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-24-2 CAPLUS
CN Piperidine, 1-(3,5-dichlorobenzoyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-
1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-25-3 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-26-4 CAPLUS
CN Piperidine, 1-(2,2-dimethyl-1-oxopropyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-27-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-28-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, propyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-29-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-30-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-31-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-32-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-53-3 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-34-4 CAPLUS
 CN Piperidine, 1-(butylsulfonyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-35-5 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(propylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-36-6 CAPLUS
CN 1-Piperidinesulfonamide, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-37-7 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-38-8 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 216524-39-9 CAPLUS
CN Piperidine, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-[5-(4-fluorophenyl)-
4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 216524-40 2 CAPLUS
 CN Piperidine, 1-(2,1,3-benzoxadiazol-4-ylsulfonyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216524-41-3 CAPLUS

CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-42-4 CAPLUS
 CN Piperidine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 216524-43-5 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[5-(2-pyridinyl)-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 216524-44-6 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-45-7 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[5-(phenylsulfonyl)-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 216524-46-8 CAPLUS
 CN Piperidine, 1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)





RN 216524-47-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(5-methylisoquinolin-1-yl)sulfonyl- (9CI) (CA INDEX NAME)




RN 216524-48-0 CAPLUS

CN Piperidine, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-49-1 CAPLUS
 CN Piperidine, 1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-50-4 CAPLUS
 CN Piperidine, 1-[(5-bromo-2-methoxyphenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-5i-5 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(5-methoxy-2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-52-6 CAPLUS
CN Piperidine, 1-[(2,3-dichlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 16524-53-9 CAPLUS
 CN Piperidine, 1-[(2,4-dichlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-54-8 CAPLUS
 CN Piperidine, 1-[(2,5-dichlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-55-9 CAPLUS
CN Piperidine, 1-[(2,6-dichlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-56-0 CAPLUS
 CN Piperidine, 1-[(3,4-dichlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-57-1 CAPLUS
 CN Piperidine, 1-[(3,5-dichlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-58-2 CAPLUS
CN Piperidine, 1-[(2,4-difluorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-59-3 CAPTUS
 CN Piperidine, 1-[(2,6-difluorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-60-6 CAPLUS
CN Piperidine, 1-[(3,4-difluorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-61-7 CAPLUS
CN Piperidine, 1-[(2-chlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-62-8 CAPLUS
CN Piperidine, 1-[(2-bromophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 21654-63-9 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-64-0 APLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




216524-65-1 CAPLUS
 Piperidine, 1-[(2-cyanophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-66-2 CAPLUS
 CN riperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[2-(methylsulfonyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-67-3 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[2-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




216524-00-4 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(3-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-69-5 CAPLUS
CN Piperidine, 1-[(3-chlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 210524-70-8 CAPLUS
 CN Piperidine, 1-[(3-bromophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-71-9 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 215424-72-0 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-73-1 CAPLUS
 CN Piperidine, 1-[(3-cyanophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-74-2 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-75-3 CAPLUS
 CN Piperidine, 1-[(4-chlorophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-76-4 CAPLUS
 CN Piperidine, 1-[(4-bromophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-77-5 CAPLUS
CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-78-6 CAPLOS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-79-7. CAPLUS
CN Piperidine, 1-[(4-cyanophenyl)sulfonyl]-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RM 216524-80-0 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[4-(methylsulfonyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-81-1 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-93-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-94-6 CAPLUS
CN Morpholine, 4-[[4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-96-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216524-98-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216525-00-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216525-02-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216525-03-0 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 216525-04-1 CAPLUS
 CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)




RN 216525-05-2 CAPLUS
 CN Piperidine, 1-(4-bromobenzoyl)-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-06-3 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-cyanobenzoyl)- (9CI) (CA INDEX NAME)




RN 216525-07-4 CAPLUS


CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216525-08-5 CAPLUS
 CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 216525-09-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 216525-10-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 216525-11-0 CAPLUS

CN Piperidine, 1-(4-chlorobenzoyl)-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-12-1 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 216525-13-2 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 216525-14-3 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216525-15-4 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 216525-16-5 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(3,4-difluorobenzoyl)- (9CI) (CA INDEX NAME)





RN 216525-17-6 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(3,5-difluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 216525-18-7 CAPLUS

CN Piperidine, 1-acetyl-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-19-8 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(5-isoxazolylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216525-20-1 CAPLUS

CN Piperidine, 1-benzoyl-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-21-2 CAPLUS

CN Piperidine, 1-(2-chlorobenzoyl)-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-23-4 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(3-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 216525-25-6 CAPLUS

CN Piperidine, 1-(3-chlorobenzoyl)-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-27-8 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 216525-29-0 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216525-31-4 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216525-33-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 216525-34-7 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 216525-36-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-

pyrazol-3-yl]-, 2-propynyl ester (9CI) (CA INDEX NAME)




RN 216525-39-2 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 216525-41-6 CAPLUS

CN Piperidine, 1-[(4-bromophenyl)sulfonyl]-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-43-8 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 216525-46-1 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(4-chlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 216525-48-3 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 216525-51-8 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(ethylsulfonyl)- (9CI) (CA INDEX NAME)




RN 216525-53-0 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 216525-55-2 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 216525-57-4 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 216525-59-6 CAPLUS

CN Piperidine, 1-[(3-bromophenyl)sulfonyl]-4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 216525-61-0 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 216525-63-2 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(3-chlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 216525-64-3 CAPLUS

CN 1-Piperidinesulfonamide, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 216525-65-4 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 216525-66-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 216525-67-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 216525-68-7 CAPLUS

CN Morpholine, 4-[[4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 216525-71-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 216525-72-3 CAPLUS



CN 1-Piperidinecarboxamide, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 216525-73-4 CAPLUS
 CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216577-31-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





PAGE 1-A

PAGE 2-A




RN 271574-56-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271574-57-3 CAPLUS
 CN Piperazine, 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271574-59-5 CAPLUS
 CN 1-Piperazinebutanoic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-.gamma.-oxo-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 271574-68-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 271575-06-5 CAPLUS



CN 1-Piperazinecarboxylic acid, 4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-
 , ethyl ester (9CI) (CA INDEX NAME)




RN 271575-63-4 CAPLUS

CN 2,6-Piperazinedione, 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-20-6 CAPLUS

CN Piperidine, 1-acetyl-4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-21-7 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-22-8 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methanesulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-23-9 CAPLUS
CN Pyridine, 4-[3-(4-chlorophenyl)-5-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-24-0 CAPLUS
 CN Pyridine, 4-[3-(4-chlorophenyl)-5-[1-(2-propenyl)-4-piperidinyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-25-1 CAPLUS
 CN Pyridine, 4-[3-(4-chlorophenyl)-5-[1-(2-propynyl)-4-piperidinyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 271576-28-4 CAPLUS
 CN Pyridine, 4-[3-[1-(1-methylethyl)-4-piperidinyl]-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 271576-48-8 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(1-iminoethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-49-9 CAPLUS
 CN 1-Piperidinecarboximidamide, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





● HCl

RN 271576-50-2 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-


10/024,665

(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-51-3 CAPLUS
CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-62-6 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-
 [(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-78-4 CAPLUS
 CN Piperidine, 1-acetyl-3-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-79-5 CAPLUS
 CN Piperidine, 3-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 271576-80-8P 271576-81-9P 271576-82-0P
 271576-83-1P 271576-84-2P 271576-85-3P
 271576-86-4P 271576-87-5P 271576-88-6P
 271576-89-7P 271576-90-0P 271576-91-1P
 271576-92-2P 271576-93-3P 271576-95-5P
 271576-97-7P 271576-99-9P 271577-01-6P
 271577-28-7P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpyrazoles as p38 kinase inhibitors)


RN 271576-80-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-81-9 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




● HCl

RN 271576-82-0 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





RN 271576-83-1 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 271576-82-0
 CMF C21 H22 Cl N5 O2

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4



Double bond geometry as shown.




RN 271576-84-2 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(2-hydroxy-2-methyl-1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 271576-85-3 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-[(2S)-2-hydroxy-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 271576-86-4 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-[(2R)-2-hydroxy-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 271576-87-5 CAPLUS



CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-[(2R)-hydroxyphenylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271576-88-6 CAPLUS
 CN Piperidine, 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 271576-89-7 CAPLUS
 CN Piperidine, 1-(hydroxyacetyl)-4-[4-(4-pyrimidinyl)-5-[4-

(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 271576-90-0 CAPLUS



CN Piperidine, 1-(hydroxyacetyl)-4-[4-(4-pyrimidinyl)-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 271576-91-1 CAPLUS



CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-

(hydroxyacetyl)- (9CI) (CA INDEX NAME)





RN 271576-92-2 CAPLUS

CN Piperidine, 4-[5-(3-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)





RN 271576-93-3 CAPLUS

CN Piperidine, 1-(hydroxyacetyl)-4-[4-(4-pyrimidinyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 271576-95-5 CAPLUS
 CN 1-Piperidineethanol, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-97-7 CAPLUS
 CN Pyrimidine, 4-[3-(4-chlorophenyl)-5-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271576-99-9 CAPLUS
 CN 1-Piperidineethanol, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271577-01-6 CAPLUS

CN 1-Piperidineethanol, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-.beta.-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271577-28-7 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(2-hydroxy-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





IT **271577-27-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of heteroarylpyrazoles as p38 kinase inhibitors)


RN 271577-27-6 CAPLUS

CN Piperidine, 1-[2-(acetyloxy)-2-methyl-1-oxopropyl]-4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2003:92403 CAPLUS

DN 138:137307

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew
 J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi

PA G.D. Searle & Company, USA

SO U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

*Same as
#4.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6514977	B1	20030204	US 1998-196623	19981120
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, TJ, LV, FI, RO			
	BR 9915420	A	20000602	BR 1999-15420	19991117
	EE 200100268	A	20021210	EE 2001-268	19991117
	US 6525059	B1	20030225	US 2000-513351	20000224
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
	US 6423713	B1	20020723	US 2001-918481	20010731
PRAI	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		
	US 1998-196623	A	19981120		
	WO 1999-US26007	W	19991117		
OS	MARPAT 138:137307				
AB	Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prep'd. by soln. phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COME (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compd. II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 .mu.M and inhibited tumor necrosis factor .alpha. (TNF.alpha.) and interleukin 1.beta. (IL-1.beta.) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 .mu.M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and				


TNF.alpha..

IT 271574-55-1P 271574-58-4P

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 271574-55-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-1-(2-propynyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 271574-58-4 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-.gamma.-oxo- (9CI) (CA INDEX NAME)



PAGE 1-A





IT 216505-87-2P 216505-90-7P 216505-93-0P
216505-98-5P 216506-00-2P 216523-64-7P
216523-65-8P 216523-66-9P 216523-67-0P
216523-68-1P 216523-69-2P 216523-70-5P
216523-71-6P 216523-72-7P 216523-73-8P
216523-74-9P 216523-75-0P 216523-76-1P
216523-77-2P 216523-78-3P 216523-79-4P
216523-80-7P 216523-81-8P 216523-82-9P
216523-83-0P 216523-84-1P 216523-85-2P
216523-86-3P 216523-87-4P 216523-88-5P
216523-89-6P 216523-90-9P 216523-91-0P
216523-92-1P 216523-93-2P 216523-94-3P
216523-95-4P 216523-96-5P 216523-97-6P
216523-98-7P 216523-99-8P 216524-00-4P
216524-01-5P 216524-02-6P 216524-03-7P
216524-04-8P 216524-05-9P 216524-06-0P
216524-07-1P 216524-08-2P 216524-09-3P
216524-10-6P 216524-11-7P 216524-12-8P
216524-13-9P 216524-14-0P 216524-15-1P
216524-16-2P 216524-17-3P 216524-18-4P
216524-19-5P 216524-20-8P 216524-21-9P
216524-22-0P 216524-23-1P 216524-24-2P
216524-25-3P 216524-26-4P 216524-27-5P
216524-28-6P 216524-29-7P 216524-30-0P
216524-31-1P 216524-32-2P 216524-33-3P
216524-34-4P 216524-35-5P 216524-36-6P
216524-37-7P 216524-38-8P 216524-39-9P
216524-40-2P 216524-41-3P 216524-42-4P
216524-43-5P 216524-44-6P 216524-45-7P
216524-46-8P 216524-47-9P 216524-48-0P
216524-49-1P 216524-50-4P 216524-51-5P
216524-52-6P 216524-53-7P 216524-54-8P
216524-55-9P 216524-56-0P 216524-57-1P
216524-58-2P 216524-59-3P 216524-60-6P
216524-61-7P 216524-62-8P 216524-63-9P
216524-64-0P 216524-65-1P 216524-66-2P
216524-67-3P 216524-68-4P 216524-69-5P
216524-70-8P 216524-71-9P 216524-72-0P
216524-73-1P 216524-74-2P 216524-75-3P
216524-76-4P 216524-77-5P 216524-78-6P
216524-79-7P 216524-80-0P 216524-81-1P
216524-93-5P 216524-94-6P 216524-96-8P
216524-98-0P 216525-00-7P 216525-02-9P
216525-03-0P 216525-04-1P 216525-05-2P
216525-06-3P 216525-07-4P 216525-08-5P
216525-09-6P 216525-10-9P 216525-11-0P

216525-12-1P 216525-13-2P 216525-14-3P
 216525-15-4P 216525-16-5P 216525-17-6P
 216525-18-7P 216525-19-8P 216525-20-1P
 216525-21-2P 216525-23-4P 216525-25-6P
 216525-27-8P 216525-29-0P 216525-31-4P
 216525-33-6P 216525-34-7P 216525-36-9P
 216525-39-2P 216525-41-6P 216525-43-8P
 216525-46-1P 216525-48-3P 216525-51-8P
 216525-53-0P 216525-55-2P 216525-57-4P
 216525-59-6P 216525-61-0P 216525-63-2P
 216525-64-3P 216525-65-4P 216525-66-5P
 216525-67-6P 216525-68-7P 216525-69-8P
 216525-70-1P 216525-71-2P 216525-72-3P
 216525-73-4P 216577-31-0P 271574-56-2P
 271574-57-3P 271574-59-5P 271574-68-6P
 271575-06-5P 271575-63-4P 271576-20-6P
 271576-21-7P 271576-22-8P 271576-23-9P
 271576-24-0P 271576-25-1P 271576-28-4P
 271576-48-8P 271576-49-9P 271576-50-2P
 271576-51-3P 271576-62-6P 271576-78-4P
 271576-79-5P 493017-40-6P, 5-(N-Isopropyl-4-piperidinyl)-
 4-(4-pyrimidinyl)-3-(4-fluorophenyl)pyrazole **493017-96-2P**



RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase
 inhibitors by cyclocondensation of hydrazines with ketones)



RN 216505-87-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-
 pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A






PAGE 2-A



FN 493017-96-2 CAPLUS
 CN Piperidine, 1-acetyl-4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:42906 CAPLUS
 DN 138:100900
 TI Novel ligands and libraries of ligands
 IN Braisted, Andrew C.; Erlanson, Daniel A.; Jacobs, Jeffrey W.
 PA USA
 SO U.S. Pat. Appl. Publ., 73 pp., Cont.-in-part of U. S. Ser. No. 121,216.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

not prior.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003013125	A1	20030116	US 2002-143455	20020510
	US 6335155	B1	20020101	US 1998-105372	19980626
	US 2002022233	A1	20020221	US 2001-981547	20011017
	US 2002150947	A1	20021017	US 2001-990421	20011121
	US 2002081621	A1	20020627	US 2002-82046	20020220
	US 2002155505	A1	20021024	US 2002-121216	20020410
PRAI	US 1998-105372	A3	19980626		
	US 2000-252294P	P	20001121		
	US 2001-981547	A2	20011017		
	US 2001-990421	A3	20011121		
	US 2002-121216	A2	20020410		
	US 2001-310725P	P	20010807		
	US 2002-43833	A1	20020111		

OS MARPAT 138:100900

AB In general, the present invention expands upon the general tethering approach described above and provides novel compds. and libraries of compds. for use in this approach. Specifically, the novel compds. and libraries described herein provide powerful tools for the development of drug leads, and are useful for the identification of fragments that bind weakly, or with moderate binding affinity, to a biol. target site of interest. A structure-activity relation (SAR) can be developed using information from a tethering expt. in much the same way SAR is developed using traditional assays. For example, ligand candidates were strongly selected against the E. coli thymidylate synthase (TS).


IT 485800-23-5

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (interleukin-2/interleukin-2 receptor .alpha. inhibition by; novel ligands and libraries of ligands for the development of drug leads and structure-activity relations)

RN 485800-23-5 CAPLUS

CN Pentanamide, N-(aminoiminomethyl)-2-[[2-[4-[3-(2,3-dichlorophenyl)-1-methyl-1H-pyrazol-5-yl]-1-piperidinyl]-2-oxoethyl]amino]-4-methyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 7 OF 25' CAPLUS COPYRIGHT 2003 ACS
 AN 2002:736252 CAPLUS
 DN 137:263031
 TI Preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors
 IN Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Zlatoidsky, Pavol
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074767	A1	20020926	WO 2002-SE472	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI SE 2001-902 A 20010315

OS MARPAT 137:263031

AB The title compds. [I; X = NR1, O, S; Y1, Y2 = O, S; Z = SO, SO2; m = 1, 2; A = a bond, alkyl, haloalkyl, etc.; R1 = H, alkyl, haloalkyl; R2, R3 = H, halo, alkyl, etc.; R4 = H, halo, alkyl, haloalkyl; R5 = monocyclic, bicyclic or tricyclic group selected from (un)substituted cycloalkyl, aryl, heterocycloalkyl, heteroaryl], useful as metalloproteinase inhibitors, esp. as inhibitors of MMP12, were prepd. Thus, reacting 1-[4-(4-fluorophenyl)phenyl]piperazine and 2-(2,5-dioxo-4-imidazolidinyl)-1-ethanesulfonyl chloride (prepn. given) in the presence Et3N in CH2Cl2 afforded II.

IT 459814-34-7P 459814-35-8P 459814-42-7P
 459814-43-8P 459815-19-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors)

RN 459814-34-7 CAPLUS

CN Piperidine, 1-[[[(4R)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]-4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459814-35-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[[[(4R)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459814-42-7 CAPLUS

CN Piperidine, 1-[[[(4S)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]-4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459814-43-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[[[(4S)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459815-19-1 CAPLUS

CN Piperidine, 4-[5-(2-furanyl)-1H-pyrazol-3-yl]-1-[[[(4S)-4-methyl-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:736236 CAPLUS
 DN 137:247696
 TI Preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors
 IN Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Zlatoidsky, Pavol
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074750	A1	20020926	WO 2002-SE475	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI SE 2001-902	A	20010315		
SE 2001-903	A	20010315		

OS MARPAT 137:247696

AB The title compds. [I; X = NR1, O, S; B = C, CH, and is a point of attachment of one or more other functional groups or side chains; Y1, Y2 = O, S; R1 = H, alkyl, haloalkyl], useful in the treatment of a disease or condition mediated by one or more metalloproteinase enzymes (no biol. data), were prepd. E.g., a 4-step synthesis of II, starting with 4-(4-chlorophenyl)benzaldehyde, was given.

IT ~~459814-34-7P~~ 459814-35-8P 459814-42-7P

459814-43-8P 459815-19-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors)

RN 459814-34-7 CAPLUS

CN Piperidine, 1-[[[(4R)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]-4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459814-35-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[[[(4R)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459814-42-7 CAPLUS

CN Piperidine, 1-[[[(4S)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]-4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459814-43-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[[[(4S)-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459815-19-1 CAPLUS

CN Piperidine, 4-[5-(2-furanyl)-1H-pyrazol-3-yl]-1-[[[(4S)-4-methyl-2,5-dioxo-4-imidazolidinyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2002:695975 CAPLUS

DN 137:232913

TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors

IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070511	A1	20020912	WO 2002-US6479	20020302
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003092732	A1	20030515	US 2002-90582	20020304
	US 2003096827	A1	20030522	US 2002-90288	20020304
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		

OS MARPAT 137:232913

AB Compds. W-(CR6R7)yCH(G)(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, hexahydro-1-azepinyl, 1-piperazinyl, cyclopentyl, cyclohexyl, cycloheptyl, amino, (cyclo)alkylamino; R4-R6 = H, (un)substituted alkyl, amino, alkylamino, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, or heterocyclyl; or CR4R5 or C6R7 is a spirocycloalkyl ring; r, s = 0 or 1; x = 0-4; y = 0-2; G = alkenyl, arylalkenyl, hydroxy, heteroaryl, cyano, functionalized alkyl or alkenyl, etc.; W = amino, alkylamino, hydroxy, alkoxy, carbamoyl, amidino, cycloalkyl, heteroaryl, heterocyclyl, etc.] were prepd. as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepd. by a soln.-phase peptide coupling/deprotection scheme.

IT 457903-98-9P 457903-99-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457903-98-9 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-(acetylamino)-N-[(1S)-2-[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457903-99-0 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-[4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-1-piperidinyl]-2-oxoethyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2002:658095 CAPLUS

DN 137:201331

TI Preparation of heterocyclic substituted cycloalkanecarboxamides as dopamine D3 receptor ligands

IN Hendrix, James A.; Hemmerle, Horst; Urmann, Matthias; Shutske, Gregory; Strupczewski, Joseph T.; Bordeau, Kenneth J.; Jurcak, John G.; Nieduzak, Thaddeus; Jackson, Sharon Anne; Angell, Paul; Fink, David M.; Sabuco, Jean-Francois; Chiang, Yulin; Collar, Nicola

PA Aventis Pharmaceuticals Inc., USA; Carey, James P.; Lee, George E.

SO PCT Int. Appl., 392 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066446	A1	20020829	WO 2002-US4713	20020215
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2001-269672P P 20010216

GB 2001-17577 A 20010719

OS MARPAT 137:201331

AB The title compds. [I; A = CH, N; n = 1-2; when n = 1, yr = 0 or 2; when n = 2, yr = 0; g = 1-2; R3 = H, alkyl, (CH2)wPh; w = 1-3; R = (un)substituted benzothienyl, pyrazinyl, pyridyl, etc.; BCO = (CR19C20)DCO, II, III, etc.; R19, R20 = H, OH, alkyl; R21-R23 = H, alkyl; d = 3-4; R1 = H, alkyl, etc.; R2 = 3-(imidazol-1-yl)propyl, trans-4-methylcyclohexyl, trans-4-ethylcyclohexyl, etc.] that display selective binding to dopamine D3 receptors, and therefore are useful in treating central nervous system disorders such as psychotic disorders, substance dependence, substance abuse, dyskinetic disorders (e.g., Parkinson's disease, parkinsonism, neuroleptic-induced tardive dyskinesia, Gilles de la Tourette syndrome and Huntington's disease), dementia, anxiety disorders, sleep disorders, circadian rhythm disorders and mood disorders, were prepd. E.g., a multi-step synthesis of trans/trans-IV was described.. Biol. data for more than 1000 compds. I were given. The subject invention is also directed towards processes for the prepn. of the compds. I as well as methods for making and using the compds. as imaging agents for dopamine D3 receptors.

IT 452907-32-3P 452907-35-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic substituted cycloalkanecarboxamides as dopamine D3 receptor ligands)

RN 452907-32-3 CAPLUS

CN Piperidine, 1-[[[(1R,2R)-2-[(4-thieno[2,3-d]isoxazol-3-yl)-1-piperidinyl)methyl]cyclopropyl]carbonyl]-4-[5-(2-thienyl)-1H-pyrazol-3-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 452907-35-6 CAPLUS

CN Piperidine, 4-[5-(2-furanyl)-1H-pyrazol-3-yl]-1-[[(1R,2R)-2-[(4-thieno[2,3-d]isoxazol-3-yl-1-piperidinyl)methyl]cyclopropyl]carbonyl]-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2001:833302 CAPLUS

DN 135:371628

TI Preparation of amino substituted dibenzothiophenes for the treatment of disorders mediated by the neuropeptide Y5 receptor

IN Block, Michael Howard; Donald, Craig Samuel; Foote, Kevin Michael; Brittain, David Robert

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085714	A1	20011115	WO 2001-GB1899	20010501
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1278739	A1	20030129	EP 2001-925687	20010501
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001010548	A	20030401	BR 2001-10548	20010501
	NO 2002005286	A	20021104	NO 2002-5286	20021104
PRAI	GB 2000-10757	A	20000505		
	WO 2001-GB1899	W	20010501		

OS MARPAT 135:371628

AB The title compds. [I; X = NHCOAR3, II; R1 = CN, halo, CF3, etc.; R2 = halo, CN, OH, etc.; A = NRa, O, a direct bond; Ra = H, alkyl, alkenyl, etc.; R3 = H, alkyl, alkenyl, etc.; R4 = halo, NO2, CN, etc.; x = 0-4; y = 0-3; z = 0-3; n = 0-2], useful in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, were prepd. and formulated. Thus, reacting 2-aminodibenzothiophene with 2-(1,2,4-triazol-1-yl)acetic acid in the presence of 1-hydroxybenztriazole and EDAC in DMF afforded I [X = 2-NHCOAR3; A = a direct bond; R3 = (1,2,4-triazol-1-yl)methyl; R1, R2 = H; n = 0]. In general, compds. I showed IC50 of 0.0002-200 .mu.M against neuropeptide Y5 receptor binding.


IT 373356-27-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino substituted dibenzothiophenes for the treatment of disorders mediated by the neuropeptide Y5 receptor)


RN 373356-27-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(5,5-dioxido-2-dibenzothienyl)-4-[5-(2-furanyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:819302 CAPLUS
 DN 136:232281
 TI Synthesis of new macrocycles from 1-pyrazolylbenzimidazole-2-thione
 AU Ahabchane, N. H.; Essassi, E. M.; Bellan, J.; Lopez, L.; Lamand, L.
 CS Laboratoire de chimie organique heterocyclique, Faculte des Sciences,
 Universite Mohamed V, Morocco
 SO Phosphorus, Sulfur and Silicon and the Related Elements (2001), 173,
 175-192
 CODEN: PSSLEC; ISSN: 1042-6507
 PB Gordon & Breach Science Publishers
 DT Journal
 LA French
 AB During the condensation between 1-[3-phenylpyrazol-5-yl]benzimidazole-2-
 thione and ClCH₂(CH₂OCH₂)₃CH₂Cl on the one hand, and between
 1,8(1,11)bis-[1-[3-phenylpyrazol-5-yl]benzimidazol-2-
 yl]mercaptotri(tetra)ethylene glycol and ClCH₂(CH₂OCH₂)_nCH₂Cl [n = 3, 2]
 on the other hand, using phase transfer catalysis, new macrocycles
 possessing various structures have been isolated which contain one or two
 pyrazolylbenzimidazole subcyclic units within the polyether chain.
 IT **403706-44-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of crown ethers from 1-pyrazolylbenzimidazole-2-thione)
 RN 403706-44-5 CAPLUS
 CN 2H-Benzimidazole-2-thione, 1,3-dihydro-1-(5-phenyl-1H-pyrazol-3-yl)-3-[2-
 [2-[2-[1-(5-phenyl-1H-pyrazol-3-yl)-1H-benzimidazol-2-
 yl]thio]ethoxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2001:662562 CAPLUS
DN 135:352346
TI From Hit to Lead. Analyzing Structure-Profile Relationships
AU Poulain, Rebecca; Horvath, Dragos; Bonnet, Beatrice; Eckhoff, Christian;
Chapelain, Beatrice; Bodinier, Marie-Christine; Deprez, Benoit
CS Department of Chemistry, CEREP, Lille, F-59000, Fr.
SO Journal of Medicinal Chemistry (2001), 44(21), 3391-3401
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Two compds., (piperidine and piperazine carboxylic acid derivs.) obtained by random screening, and displaying micromolar activities on the .mu. opiate receptor were used as starting points for optimization. In that work, the traditional concept of the activity of a compd. (related to one or a few targets) was extended to the comprehensive pharmacol. profile of that compd. on more than 70 receptors, transporters, and channels relevant to a CNS-oriented project. Using the two complementary design strategies based on two similarity concepts described in the previous paper, we have obtained analogs with IC50 values ranging between 0.9 nM and a few micromolar on the .mu. receptor and displaying qual. different profiles. We discuss here, both on a case-by-case basis and from a statistical standpoint, the pharmacol. profiles in light of the two similarity concepts.
IT **372956-14-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(piperidine- and piperazine carboxylic acid deriv: opioid receptor structure-activity relationship, and compd. prepn.)
RN 372956-14-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-[5-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]-N-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

*Same as
#13*

PAGE 1-A



PAGE 2-A



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:338350 CAPLUS
 DN 134:326537
 TI Preparation of acylazole derivatives as kainic acid neurocytotoxicity inhibitors
 IN Shishikura, Jun-ichi; Inami, Hiroshi; Kaku, Hidetaka; Tsutsumi, Rie; Yamashita, Hiroshi; Ohno, Kazushige
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032173	A1	20010510	WO 2000-JP7572	20001027
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 1999-310035	A	19991029		
OS	MARPAT 134:326537				
AB	Kainic acid neurocytotoxicity inhibitors contg. as the active ingredient acyl-nitrogen-contg. 5-membered heterocycle derivs. or pharmaceutically acceptable salts thereof [I; A = O, S; X, Y = C, CH, N; Z = C, CH, N, O; n = 0,1; the solid line accompanied with a dotted line represents a single or double bond; R1, R3, R4 = each (un)substituted lower alkyl, alkenyl, hydrocarbyl, heterocyclyl, aryl-lower alkyl, heteroaryl-lower alkyl, aryl-lower alkenyl, or heteroaryl-lower alkenyl: P2 = H, (un)substituted lower alkyl; R5, R6 = absent, H, (un)substituted lower alkyl or R3 and R5 or R6, or R4 and R6 are united to form an (un)substituted cycloalkane, cycloalkene, heterocycloalkane, or heterocycloalkene] are prepd. Also prepd. are 1-acyl-2-pyrazoline derivs. [II; A, n, R1, R2 = same as above; one of R3 and R4 = (un)substituted pyridyl or pyrazyl and the other = each (un)substituted lower alkyl, alkenyl, hydrocarbyl, heterocyclyl, aryl-lower alkyl, heteroaryl-lower alkyl, aryl-lower alkenyl, or heteroaryl-lower alkenyl; or R3 and R5 or R6 are united to form an (un)substituted cycloalkane, cycloalkene, heterocycloalkane, or heterocycloalkene and R4 = each (un)substituted lower alkyl, alkenyl, hydrocarbyl, heterocyclyl, aryl-lower alkyl, heteroaryl-lower alkyl, aryl-lower alkenyl, or heteroaryl-lower alkenyl] or pharmaceutically acceptable salts thereof. These compds. also possess noncompetitive antagonism against AMPA (2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid) receptor and are useful as nerve cell protectants or therapeutics for epilepsy. Thus, a mixt. of chalcone, hydrazine monohydrate, and ethanol was refluxed for 1 h to give 1-benzoyl-4,5-dihydro-3,5-diphenyl-1H-pyrazole (III). III and (+)-3-(1-benzoyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine showed IC50 of 2.6 and 1.3 .mu.M, resp., for inhibiting the.				
IT	336795-08-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

(prepn. of acylazole derivs. as kainic acid neurocytotoxicity inhibitors, nerve cell protectants, and antiepileptics)

RN 336795-08-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1-benzoyl-4,5-dihydro-3-phenyl-1H-pyrazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 336796-45-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of acylazole derivs. as kainic acid neurocytotoxicity inhibitors, nerve cell protectants, and antiepileptics)

RN 336796-45-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-(1-benzoyl-4,5-dihydro-3-phenyl-1H-pyrazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2001:115118 CAPLUS

DN 134:163065

TI Preparation of hydroxamic acid and N-formyl hydroxylamine derivatives as antibacterial agents

IN Pratt, Lisa Marie; Keavey, Kenneth Noel; Pain, Gilles Denis; Mounier, Laurent Franck

PA British Biotech Pharmaceuticals Limited, UK

SO PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010834	A2	20010215	WO 2000-GB3078	20000810
	WO 2001010834	A3	20010628		
	W:	AE, AU, BR, BY, CA, CN, CZ, DZ, EE, GB, GE, HU, ID, IL, IN, IS, JP, KE, KR, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, US, VN, ZA, ZW			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	EP 1202968	A2	20020508	EP 2000-949820	20000810
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY			
	BR 2000013112	A	20020611	BR 2000-13112	20000810
	JP 2003506438	T2	20030218	JP 2001-515301	20000810
	NO 2002000621	A	20020409	NO 2002-621	20020208
PRAI	GB 1999-18869	A	19990810		
	GB 1999-27093	A	19991116		
	WO 2000-GB3078	W	20000810		

OS MARPAT 134:163065

AB Selected compds. QCH(R1)CH(R2)C(O)A (I) and pharmaceutical and veterinary compns. comprising such compds. are antibacterial agents with respect to a range of Gram-pos. and Gram-neg. organisms. In I, Q = -N(OH)C(O)H or -C(O)NH(OH); R1 = H, C1-C6 alkyl or C1-C6 alkyl substituted by .gtoreq. halogen atoms, or, except when Q is -N(OH)C(O)H, hydroxy, C1-C6 alkoxy, C1-C6 alkenyloxy, amino, C1-C6 alkylamino, or di-(C1-C6 alkyl)amino; R2 = substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)-; and A = -NHCHR4C(O)NR5R6 or -NR5R6, wherein R4 = side chain of a natural or non-natural .alpha.-amino acid, and R5 and R6 when taken together with the N atom to which they are attached form a satd. heterocyclic 1st ring of 5 to 7 atoms (piperidine and piperazine in the examples). In general, the compds. of the examples are more active against the Gram pos. S. capitis than the Gram neg. E. coli. Test results are also reported for 2R-cyclopentylmethyl-3-(formylhydroxyamino)-N-(1S-[4-[4-(4-hydroxypiperidine-1-carbonyl)phenoxy]piperidine-1-carbonyl]-2,2-dimethylpropyl)propionamide against certain respiratory tract pathogens. Although the methods of prepn. are not claimed, .apprx.95 example prepn. are included.


IT **325795-48-0P**, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (1S-[4-(5-furan-2-yl-2H-pyrazol-3-yl)piperidine-1-carbonyl]-2,2-dimethylpropyl)amide **325795-49-1P**, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (2,2-dimethyl-1S-[4-(5-phenyl-2H-pyrazol-3-yl)piperidine-1-carbonyl]propyl)amide **325795-52-6P**, 2R-[(Formylhydroxyamino)methyl]hexanoic acid (1S-[4-[5-(2-chlorophenyl)-2H-pyrazol-3-yl]piperidine-1-carbonyl]-2,2-dimethylpropyl)amide
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of hydroxamic acid and N-formyl hydroxylamine derivs. as
 antibacterial agents)

RN 325795-48-0 CAPLUS

CN Hexanamide, 2-[(formylhydroxyamino)methyl]-N-[(1S)-1-[[4-[5-(2-furanyl)-1H-pyrazol-3-yl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]-, (2R)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 325795-49-1 CAPLUS

CN Hexanamide, N-[(1S)-2,2-dimethyl-1-[[4-(5-phenyl-1H-pyrazol-3-yl)-1-piperidinyl]carbonyl]propyl]-2-[(formylhydroxyamino)methyl]-, (2R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 325795-52-6 CAPLUS

CN Hexanamide, N-[(1S)-1-[[4-[5-(2-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]-2-[(formylhydroxyamino)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/024,665



L9 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2000:725463 CAPLUS

DN 133:296374

TI Preparation of pyrrolidine modulators of chemokine receptor activity
IN Chapman, Kevin; Hale, Jeffrey; Kim, Dooseop; Lynch, Christopher; Shah, Shrenik; Shankaran, Kothandaraman; Shen, Dong-ming; Willoughby, Christopher; Maccoss, Malcolm; Mills, Sander G.; Loebach, Jennifer L.; Guthikonda, Ravindra N.

PA Merck & Co., Inc., USA; et al.

SO PCT Int. Appl., 455 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059502	A1	20001012	WO 2000-US8996	20000405
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6248755	B1	20010619	US 2000-542617	20000404
	EP 1171122	A1	20020116	EP 2000-921700	20000405
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002541103	T2	20021203	JP 2000-609066	20000405
PRAI	US 1999-128033P	P	19990406		
	WO 2000-US8996	W	20000405		

OS MARPAT 133:296374

AB The title comds. [I; R1 = CO₂H, NO₂, tetrazolyl, etc.; R₂ = (un)substituted piperidino, 1,2,3,6-tetrahydropyridin-1-yl; piperidino; R₃ = (un)substituted Ph, naphthyl, heterocyclyl; R₄ = (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, etc.; R₅ = H, (un)substituted alkyl; R₄ and R₅ may be joined together to form (un)substituted cycloalkyl; R₆ = H, (un)substituted alkyl; R₁₄ = H, alkyl; n = 0-3] and their pharmaceutically acceptable salts, modulators of chemokine receptor activity, in particular, modulators of the chemokine receptors CCR-5 and/or CCR-3, and therefore useful in treating AIDS, were prepd. E.g., a multi-step synthesis of II.CF₃CO₂H was given. The comds. I had activity in binding to CCR-5 or the CCR-3 receptor, generally with an IC₅₀ of < 1 .mu.M.

IT 301209-35-8P 301209-83-6P 301209-85-8P
301209-89-2P 301210-08-2P 301210-10-6P
301210-12-8P 301210-14-0P 301218-93-9P
301218-94-0P 301218-95-1P 301218-96-2P
301218-97-3P 301218-98-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrrolidine modulators of chemokine receptor activity)

RN 301209-35-8 CAPLUS


CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-[[4-(1-ethyl-3-phenyl-1H-pyrazol-5-yl)-1-piperidinyl]methyl]-4-phenyl-, (.alpha.R,3S,4S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 301209-34-7

CMF C35 H46 N4 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 301209-83-6 CAPLUS

CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-[[4-(1-ethyl-5-phenyl-1H-pyrazol-3-yl)-1-piperidinyl]methyl]-4-phenyl-, (.alpha.R,3S,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 301209-85-8 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[5-(4-cyanophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-.alpha.-cyclohexyl-4-phenyl-, (.alpha.R,3S,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 301209-89-2 CAPLUS

CN 1-Pyrrolidineacetic acid, .alpha.-(cyclobutylmethyl)-3-[[4-(1-ethyl-3-phenyl-1H-pyrazol-5-yl)-1-piperidinyl]methyl]-4-(3-fluorophenyl)-, (.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301210-08-2 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[5-(4-cyanophenyl)-1-ethyl-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-.alpha.-cyclohexyl-4-phenyl-, (.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301210-10-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[3-(4-cyanophenyl)-1-ethyl-1H-pyrazol-5-yl]-1-piperidinyl]methyl]-.alpha.-cyclohexyl-4-phenyl-, (.alpha.R,3S,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301210-12-8 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[5-[4-(aminomethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-.alpha.-cyclohexyl-4-phenyl-, (.alpha.R,3S,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301210-14-0 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[3-[4-(aminomethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]-1-piperidinyl]methyl]-.alpha.-cyclohexyl-4-phenyl-,
(.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301218-93-9 CAPLUS

CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-[[4-[5-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-,
(.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301218-94-0 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-.alpha.-cyclohexyl-4-(3-fluorophenyl)-,
(.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301218-95-1 CAPLUS

CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-(3-fluorophenyl)-4-[[4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-, (.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301218-96-2 CAPLUS

CN 1-Pyrrolidineacetic acid, 3-[[4-[5-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-.alpha.-(1-methylethyl)-, (.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301218-97-3 CAPLUS

CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-(3-fluorophenyl)-4-[[4-[5-(2-furanyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-, (.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 301218-98-4 CAPLUS

CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-[[4-[5-[4-[(4-ethoxyphenyl)methyl]-2-furanyl]-1H-pyrazol-3-yl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-, (.alpha.R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 301219-95-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyrrolidine modulators of chemokine receptor activity)

RN 301219-95-4 CAPLUS


CN 1-Pyrrolidineacetic acid, .alpha.-cyclohexyl-3-[[4-(1-ethyl-3-phenyl-1H-pyrazol-5-yl)-1-piperidinyl]methyl]-4-phenyl-, phenylmethyl ester, (.alpha.R,3S,4S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 301219-94-3

CMF C42 H52 N4 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L9 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2003 ACS

A2 2000:368337 CAPLUS

DN 133:4656

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 1210 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6514977	B1	20030204	US 1998-196623	19981120
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9915420	A	20020122	BR 1999-15420	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	US 6525059	B1	20030225	US 2000-513351	20000224
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
PRAI	US 1998-196623	A	19981120		
	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		
	WO 1999-US26007	W	19991117		

OS MARPAT 133:4656

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepd. by reaction of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compd. II. Data for biol. activity of I were given.

IT 271574-55-1P 271574-58-4P 271576-80-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 271574-55-1 CAPLUS


3 cyclic
subs
on
pyrazole

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-1-(2-propynyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 271574-58-4 CAPLUS


CN 1-Piperazinebutanoic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-.gamma.-oxo- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A




RN 271576-80-8 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 216505-87-2P 216505-90-7P 216505-93-0P
 216505-98-5P 216506-00-2P 216523-64-7P
 216523-65-8P 216523-66-9P 216523-67-0P
 216523-68-1P 216523-69-2P 216523-70-5P
 216523-71-6P 216523-72-7P 216523-73-8P
 216523-74-9P 216523-75-0P 216523-76-1P
 216523-77-2P 216523-78-3P 216523-79-4P
 216523-80-7P 216523-81-8P 216523-82-9P
 216523-83-0P 216523-84-1P 216523-85-2P
 216523-86-3P 216523-87-4P 216523-88-5P
 216523-89-6P 216523-90-9P 216523-91-0P
 216523-92-1P 216523-93-2P 216523-94-3P
 216523-95-4P 216523-96-5P 216523-97-6P
 216523-98-7P 216523-99-8P 216524-00-4P
 216524-01-5P 216524-02-6P 216524-03-7P
 216524-04-8P 216524-05-9P 216524-06-0P
 216524-07-1P 216524-08-2P 216524-09-3P
 216524-10-6P 216524-11-7P 216524-12-8P

216524-13-9P 216524-14-0P 216524-15-1P
 216524-16-2P 216524-17-3P 216524-18-4P
 216524-19-5P 216524-20-8P 216524-21-9P
 216524-22-0P 216524-23-1P 216524-24-2P
 216524-25-3P 216524-26-4P 216524-27-5P
 216524-28-6P 216524-29-7P 216524-30-0P
 216524-31-1P 216524-32-2P 216524-33-3P
 216524-34-4P 216524-35-5P 216524-36-6P
 216524-37-7P 216524-38-8P 216524-39-9P
 216524-40-2P 216524-41-3P 216524-42-4P
 216524-43-5P 216524-44-6P 216524-45-7P
 216524-46-8P 216524-47-9P 216524-48-0P
 216524-49-1P 216524-50-4P 216524-51-5P
 216524-52-6P 216524-53-7P 216524-54-8P
 216524-55-9P 216524-56-0P 216524-57-1P
 216524-58-2P 216524-59-3P 216524-60-6P
 216524-61-7P 216524-62-8P 216524-63-9P
 216524-64-0P 216524-65-1P 216524-66-2P
 216524-67-3P 216524-68-4P 216524-69-5P
 216524-70-8P 216524-71-9P 216524-72-0P
 216524-73-1P 216524-74-2P 216524-75-3P
 216524-76-4P 216524-77-5P 216524-78-6P
 216524-79-7P 216524-80-0P 216524-81-1P
 216524-93-5P 216524-94-6P 216524-96-8P
 216524-98-0P 216525-00-7P 216525-02-9P
 216525-03-0P 216525-04-1P 216525-05-2P
 216525-06-3P 216525-07-4P 216525-08-5P
 216525-09-6P 216525-10-9P 216525-11-0P
 216525-12-1P 216525-13-2P 216525-14-3P
 216525-15-4P 216525-16-5P 216525-17-6P
 216525-18-7P 216525-19-8P 216525-20-1P
 216525-21-2P 216525-23-4P 216525-25-6P
 216525-27-8P 216525-29-0P 216525-31-4P
 216525-33-6P 216525-34-7P 216525-36-9P
 216525-39-2P 216525-41-6P 216525-43-8P
 216525-46-1P 216525-48-3P 216525-51-8P
 216525-53-0P 216525-55-2P 216525-57-4P
 216525-59-6P 216525-61-0P 216525-63-2P
 216525-64-3P 216525-65-4P 216525-66-5P
 216525-67-6P 216525-68-7P 216525-69-8P
 216525-70-1P 216525-71-2P 216525-72-3P
 216525-73-4P 216577-31-0P 271574-56-2P
 271574-57-3P 271574-59-5P 271574-68-6P
 271575-06-5P 271575-63-4P 271576-20-6P
 271576-21-7P 271576-22-8P 271576-23-9P
 271576-24-0P 271576-25-1P 271576-28-4P
 271576-48-8P 271576-49-9P 271576-50-2P
 271576-51-3P 271576-62-6P 271576-78-4P
 271576-79-5P 271576-81-9P 271576-83-1P
 271576-84-2P 271576-85-3P 271576-86-4P
 271576-87-5P 271576-88-6P 271576-89-7P
 271576-90-0P 271576-91-1P 271576-92-2P
 271576-93-3P 271576-94-4P 271576-96-6P
 271576-98-8P 271577-00-5P 271577-01-6P
 271577-02-7P 271577-05-0P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpyrazole p38 kinase inhibitors by
cyclocondensation of hydrazines with ketones)


RN 216505-87-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-90-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 271577-28-7 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-(2-hydroxy-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 1998:733144 CAPLUS

DN 130:38377

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.;
 Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.;
 Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier, Richard
 M.; Xu, Xiangdong

PA G.D. Searle and Co., USA; et al.

SO PCT Int. Appl., 828 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852940	A1	19981126	WO 1998-US10436	19980522
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9875883	A1	19981211	AU 1998-75883	19980522
	AU 754830	B2	20021128		
	ZA 9804358	A	19990524	ZA 1998-4358	19980522
	EP 1000055	A1	20000517	EP 1998-923642	19980522
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 9900527	A	20000615	EE 1999-527	19980522
	BR 9809147	A	20000801	BR 1998-0147	19980522
	JP 9808754	T2	20020319	JP 1998-556658	19980522
	NZ 501112	A	20021025	NZ 1998-501112	19980522
	NO 9905695	A	20000121	NO 1999-5695	19991119
	MX 9910759	A	20000531	MX 1999-10759	19991122
PRAI	US 1997-47570P	P	19970522		
	WO 1998-US10436	W	19980522		

OS MARPAT 130:38377

AB Title compds. [I; R1 = H, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prep'd. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title comp'd. II. Data for biol. activity of I were given.

IT 216505-87-2P 216505-90-7P 216505-93-0P
 216505-98-5P 216506-00-2P 216523-64-7P
 216523-65-8P 216523-66-9P 216523-67-0P
 216523-68-1P 216523-69-2P 216523-70-5P
 216523-71-6P 216523-72-7P 216523-73-8P
 216523-74-9P 216523-75-0P 216523-76-1P
 216523-77-2P 216523-78-3P 216523-79-4P
 216523-80-7P 216523-81-8P 216523-82-9P
 216523-83-0P 216523-84-1P 216523-85-2P
 216523-86-3P 216523-87-4P 216523-88-5P
 216523-89-6P 216523-90-9P 216523-91-0P

*3 Cyclic
 Subs
 on
 pyrazolyl*

216523-92-1P 216523-93-2P 216523-94-3P
 216523-95-4P 216523-96-5P 216523-97-6P
 216523-98-7P 216523-99-8P 216524-00-4P
 216524-01-5P 216524-02-6P 216524-03-7P
 216524-04-8P 216524-05-9P 216524-06-0P
 216524-07-1P 216524-08-2P 216524-09-3P
 216524-10-6P 216524-11-7P 216524-12-8P
 216524-13-9P 216524-14-0P 216524-15-1P
 216524-16-2P 216524-17-3P 216524-18-4P
 216524-19-5P 216524-20-8P 216524-21-9P
 216524-22-0P 216524-23-1P 216524-24-2P
 216524-25-3P 216524-26-4P 216524-27-5P
 216524-28-6P 216524-29-7P 216524-30-0P
 216524-31-1P 216524-32-2P 216524-33-3P
 216524-34-4P 216524-35-5P 216524-36-6P
 216524-37-7P 216524-38-8P 216524-39-9P
 216524-40-2P 216524-41-3P 216524-42-4P
 216524-43-5P 216524-44-6P 216524-45-7P
 216524-46-8P 216524-47-9P 216524-48-0P
 216524-49-1P 216524-50-4P 216524-51-5P
 216524-52-6P 216524-53-7P 216524-54-8P
 216524-55-9P 216524-56-0P 216524-57-1P
 216524-58-2P 216524-59-3P 216524-60-6P
 216524-61-7P 216524-62-8P 216524-63-9P
 216524-64-0P 216524-65-1P 216524-66-2P
 216524-67-3P 216524-68-4P 216524-69-5P
 216524-70-8P 216524-71-9P 216524-72-0P
 216524-73-1P 216524-74-2P 216524-75-3P
 216524-76-4P 216524-77-5P 216524-78-6P
 216524-79-7P 216524-80-0P 216524-81-1P
 216524-93-5P 216524-94-6P 216524-96-8P
 216524-98-0P 216525-00-7P 216525-02-9P
 216525-03-0P 216525-04-1P 216525-05-2P
 216525-06-3P 216525-07-4P 216525-08-5P
 216525-09-6P 216525-10-9P 216525-11-0P
 216525-12-1P 216525-13-2P 216525-14-3P
 216525-15-4P 216525-16-5P 216525-17-6P
 216525-18-7P 216525-19-8P 216525-20-1P
 216525-21-2P 216525-23-4P 216525-25-6P
 216525-27-8P 216525-29-0P 216525-31-4P
 216525-33-6P 216525-34-7P 216525-36-9P
 216525-39-2P 216525-41-6P 216525-43-8P
 216525-46-1P 216525-48-3P 216525-51-8P
 216525-53-0P 216525-55-2P 216525-57-4P
 216525-59-6P 216525-61-0P 216525-63-2P
 216525-64-3P 216525-65-4P 216525-66-5P
 216525-67-6P 216525-68-7P 216525-69-8P
 216525-70-1P 216525-71-2P 216525-72-3P
 216525-73-4P 216577-31-0P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpyrazoles as p38 kinase inhibitors)


RN 216505-87-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 216505-90-7 CAPIUS
CN 1-Piperazinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 216525-73-4 CAPLUS

CN Piperidine, 4-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 216577-31-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 1996:254691 CAPLUS

DN 124:331708

TI 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole:
A Potent, Selective Antagonist at Human Cloned Dopamine D4 Receptors

AU Rowley, Michael; Broughton, Howard B.; Collins, Ian; Baker, Raymond; Emms, Frances; Marwood, Rosemarie; Patel, Shil; Patel, Smita; Ragan, C. Ian; et al.

CS Neuroscience Research Centre, Merck Sharp and Dohme, Harlow/ Essex, CM20 2QR, UK

SO Journal of Medicinal Chemistry (1996), 39(10), 1943-5
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Based on the structure of the classical neuroleptic haloperidol, the Merck sample collection was screened using the topol. similarity probe method for compds. that might have affinity for human cloned dopamine D4 receptors, and in the hope that they might show selectivity over other subtypes. This led to 5-(4-chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole with a K_i of 61 nM at D4, and 4-fold selectivity over D2. A medicinal chem. program was initiated to improve the affinity and selectivity. Alteration of the basic nitrogen substituent gave increased affinity, while changes to the pyrazole moiety improved selectivity. The isoxazole 5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole is an antagonist with high D4 affinity and selectivity over the other human cloned dopamine receptor subtypes (K_i : hD4 3.5 nM, hD2 > 1700 nM, hD3 770 nM).


IT 156336-93-5P 156337-24-5P 156337-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(chlorophenyl(methyl)[(phenylethyl)piperidinyl]isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors)

RN 156336-93-5 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 156337-24-5 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Same as #22



RN 156337-47-2 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 1994:483041 CAPLUS

DN 121:83041

TI (Piperidinyl)pyrazoles and Analogs as Dopamine Receptor Subtype Ligands

IN Broughton, Howard Barff; Collins, Ian James; Baker, Raymond; Leeson, Paul David; Rowley, Michael

PA Merck Sharp and Dohme Ltd., UK

SO PCT Int. Appl., 76 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9410145	A1	19940511	WO 1993-GB2190	19931022
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2146019	AA	19940511	CA 1992-2146019	19931022
	AU 9453414	A1	19940524	AU 1994-53414	19931022
	AU 678186	B2	19970522		
	EP 665833	A1	19950809	EP 1993-923608	19931022
	EP 665833	B1	19990714		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 08502508	T2	19960319	JP 1993-510809	19931022
	AT 182139	E	19990715	AT 1993-923608	19931022
	ES 2133416	T3	19990916	ES 1993-923608	19931022
	US 5631269	A	19970520	US 1995-424364	19950420
PRAI	GB 1992-22263		19921023		
	GB 1992-22265		19921023		
	WO 1993-GB2190		19931022		
OS	MARPAT 121:83041				
AB	Pyrazoles and oxazoles and thiazoles I (X, Y = N, the other of X, Y = O, S, N; Q = heterocyclic ring; A = substituted Ph, pyridinyl, thioenyl, etc.; R1 = H, halo, alkyl, etc.) were disclosed. I are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment of disorders of the dopamine system, in particular schizophrenia. An example compd., 1-(4-chlorophenyl)-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]piperidine (II) was prepd. Pharmacol. test data for I were not presented.				
IT	156337-36-9				
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	([(phenyl)piperidiny]pyrazoles and analogs for treatment)				
RN	156337-36-9 CAPLUS				
CN	Piperidine, 4-[5-(4-chlorophenyl)-1,4-dimethyl-1H-pyrazol-3-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)				


Same as
#23.

IT 156336-83-3P 156336-84-4P 156336-85-5P
 156336-86-6P 156336-87-7P 156336-88-8P
 156336-89-9P 156336-90-2P 156336-91-3P
 156336-92-4P 156336-93-5P 156336-94-6P,
 4-[5-(4-Chlorophenyl)-1H-pyrazol-3-yl]-1-(3,4-dichlorophenyl)piperidine
 156336-95-7P 156336-96-8P 156336-98-0P
 156336-99-1P, 4-(5-Phenyl-1H-pyrazol-3-yl)-1-
 (phenylmethyl)piperidine 156337-00-7P 156337-01-8P
 156337-02-9P 156337-03-0P, 4-[5-(4-Chlorophenyl)-1H-
 pyrazol-3-yl]-1-[(3-methylphenyl)methyl]piperidine 156337-04-1P
 156337-05-2P 156337-06-3P 156337-07-4P
 156337-08-5P 156337-09-6P 156337-17-6P
 156337-19-8P 156337-20-1P 156337-21-2P
 156337-22-3P 156337-23-4P 156337-24-5P
 156337-25-6P 156337-26-7P 156337-33-6P
 156337-35-8P 156337-37-0P 156337-38-1P
 156337-39-2P 156337-40-5P 156337-41-6P
 156337-42-7P 156337-43-8P 156337-44-9P
 156337-45-0P 156337-46-1P 156337-47-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as antischizophrenic)


RN 156336-83-3 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(phenylmethyl)- (9CI)
 (CA INDEX NAME)



RN 156336-84-4 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 156336-85-5 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(4-

methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156336-86-6 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(2-propenyl)- (9CI)
(CA INDEX NAME)




RN 156336-87-7 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156336-88-8 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-(5-phenyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




RN 156336-89-9 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(2-thienyl)-1H-pyrazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 156336-90-2 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 156336-91-3 CAPLUS


CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 156336-92-4 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(cyclohexylmethyl)-
(9CI) (CA INDEX NAME)

RN 156336-93-5 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(2-phenylethyl)-
(9CI) (CA INDEX NAME)


RN 156336-94-6 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156336-95-7 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(3-chlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 156336-96-8 CAPLUS

CN Piperidine, 1-[(3-chlorophenyl)methyl]-4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 156336-98-0 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(2-chlorophenyl)-1H-pyrazol-3-yl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 156336-97-9


CMF C21 H21 Cl2 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 156336-99-1 CAPLUS

CN Piperidine, 1-(phenylmethyl)-4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 156337-00-7 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 156337-01-8 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156337-02-9 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156337-03-0 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156337-04-1 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156337-05-2 CAPLUS

CN Piperidine, 1-[(2-chlorophenyl)methyl]-4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 156337-06-3 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 156337-07-4 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 156337-08-5 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(3-phenylpropyl)-
 (9CI) (CA INDEX NAME)




RN 156337-09-6 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 156337-17-6 CAPLUS
 CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 156337-16-5
 CMF C22 H23 Cl2 N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 156337-19-8 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 156337-18-7


CMF C22 H23 Cl2 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 156337-20-1 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-(4-methyl-5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 156337-21-2 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 156337-22-3 CAPLUS

CN Pyridine, 2-[5-[1-(2-phenylethyl)-4-piperidinyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 156337-23-4 CAPLUS

CN 1H-Indole, 3-[[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 156337-24-5 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 156337-25-6 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(phenylmethyl)-, dihydrobromide (9CI) (CA INDEX NAME)



● 2 HBr


RN 156337-26-7 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 156337-33-6 CAPLUS
 CN Piperidine, 4-[5-(4-chlorophenyl)-4-ethyl-1H-pyrazol-3-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 156337-35-8 CAPLUS
 " Piperidine, 4-[3-(4-chlorophenyl)-1,4-dimethyl-1H-pyrazol-5-yl]-1-(phenylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 156337-34-7
 CMF C23 H26 Cl N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 156337-37-0 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1,4-dimethyl-1H-pyrazol-3-yl]-1-(phenylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 156337-36-9


CMF C23 H26 Cl N3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 156337-38-1 CAPLUS


CN Piperidine, 4-(4-methoxy-5-phenyl-1H-pyrazol-3-yl)-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 156337-39-2 CAPLUS


CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(3-phenyl-2-propenyl)-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 156337-40-5 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 156337-41-6 CAPLUS

CN Piperidine, 1-(2-furanylmethyl)-4-(4-methyl-5-phenyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




RN 156337-42-7 CAPLUS

CN Piperidine, 1-[2-(4-methoxyphenyl)ethyl]-4-(4-methyl-5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 156337-43-8 CAPLUS

CN Ethanone, 2-[4-(4-methyl-5-phenyl-1H-pyrazol-3-yl)-1-piperidinyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 156337-44-9 CAPLUS

CN Pyridine, 3-[2-[4-(4-methyl-5-phenyl-1H-pyrazol-3-yl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 156337-45-0 CAPLUS

CN Piperidine, 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 156337-46-1 CAPLUS

CN Piperidine, 4-[5-chloro-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 156337-47-1 CAPLUS

CN Piperidine, 1-[(4-chlorophenyl)methyl]-4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:49:13 ON 28 MAY 2003)

FILE 'REGISTRY' ENTERED AT 15:49:19 ON 28 MAY 2003

L1 STRUCTURE UPLOADED

L2 3 S L1 SSS SAM

L3 SCREEN 1840

L4 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L5 STRUCTURE UPLOADED

L6 QUE L5 AND L3 NOT L4

L7 1 S L6 SSS SAM

L8 406 S L6 SSS FUL

FILE 'CAPLUS' ENTERED AT 15:57:15 ON 28 MAY 2003

L9 25 S L8

FILE 'CAOLD' ENTERED AT 15:59:12 ON 28 MAY 2003

=> s l8

L10 0 L8

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.40	268.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-16.28

STN INTERNATIONAL LOGOFF AT 15:59:27 ON 28 MAY 2003